bmiMD review

bmiMD is strong on price and dose and weak on who stands behind them. It sells sermorelin in three routes and NAD⁺ in two, publishes every price without a signup gate, states the total charge for each multi-month tier, and tells you exactly how much peptide is in the injection vial. Your card is only authorized at checkout and charged once a provider confirms you are eligible. What it does not tell you is who compounds the medication or who prescribes it, canceling after the intake form is sent costs a $50 fee, and one line on the sermorelin page contradicts its own plan picker.

An online telehealth store, trading as bmiMD, Inc., selling compounded medications across four goal categories — weight loss, mood and energy, strength and cardio, and anti-aging. The catalog is sermorelin (injection, oral tablet and nasal spray), NAD⁺ (injection and nasal spray), glutathione injection, a MIC plus vitamin B12 lipotropic injection, compounded semaglutide and tirzepatide including microdose protocols, metformin, and a naltrexone-bupropion-B6 combination. A separate "Peptides — coming soon" page takes waitlist sign-ups for further peptides and states that none of them is available or cleared for compounding yet. There is no testosterone in any form, no enclomiphene and no hormone category.

Asynchronous-first telehealth with no in-person option. You place the order first; bmiMD authorizes your card, sends a HIPAA-compliant intake form, and a board-certified provider holds a same-day telehealth consultation with no scheduling. Only once the provider confirms eligibility is the payment captured; if you are not eligible, the hold is released and you pay nothing. Approved medication ships in three to five business days. Unlimited provider messaging and 24/7 support are included, with no separate consultation fee. Prices are entirely public before you create an account, which makes bmiMD easy to comparison-shop. On quality, bmiMD says a third-party lab tests every lot for potency, endotoxins, sterility and pH, and that strength is confirmed every three to six months to stay within 10% of target. What is not disclosed: no compounding pharmacy is named, only "licensed sterile compounding pharmacies throughout the United States"; and no medical director or individual clinician is named. The injection, nasal spray and NAD⁺ pages state availability in all 50 states; the sermorelin tablet page lists 49, excluding South Carolina.

Transparent in structure. Each product has a plan picker where every tier is a recurring subscription and the total charge is stated, each beside a struck-through list price. Sermorelin injection: $139 a month month-to-month, $119 a month on three months billed $357, or $99 on six months billed $594. Sermorelin tablets: $129 month-to-month, $109 on three months ($327), $89 on six ($534). Sermorelin nasal spray: $159 month-to-month, $149 on three months ($447), $129 on six ($774). NAD⁺ injection and nasal spray share one ladder: $159 month-to-month, $149 on three months ($447), $129 on six ($774) and $119 on twelve, billed as one $1,428 payment. Glutathione injection is $159 month-to-month or $149 a month on three months ($447). Shipping is free on subscriptions. One caveat: a block further down the sermorelin injection page reads "Start for $139/month. Billed quarterly", while the plan picker bills the $139 tier every month and prices the quarterly tier at $119 a month. Go by the plan picker, and confirm the billing cycle at checkout. Know the exit terms before you buy: once the pharmacy processes an order, nothing is refunded, partly used subscription periods are not refunded, and canceling after your intake form has been sent carries a $50 non-refundable fee. You can cancel or pause a subscription from your account at any time, except for a month you have already been charged for.

Compounded; not FDA-approved — and bmiMD says so itself, which deserves credit. Its FAQ states that its formulations are not FDA-approved but are made from pharmaceutical-grade ingredients, it carries a proper compounded-medication disclaimer describing the state-licensed or FDA-registered compounding facility, and it correctly caveats that its compounded microdose formulations have not been specifically studied for the effects it markets them for. On the evidence, the two headline lines sit at different tiers. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone rather than supplying it, preserving the feedback loop that exogenous growth hormone overrides — a real, well-characterized mechanism whose long-term human outcome data stays thin beyond short-term IGF-1 movement. Injected and intranasal NAD⁺ have no controlled human outcome trials; the NAD⁺ forms with human trial data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, which raise a blood level rather than demonstrate an outcome. Glutathione has essentially no controlled human outcome data. Individual results vary.